681 related articles for article (PubMed ID: 25959272)
21. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling.
Normanno N; Campiglio M; Maiello MR; De Luca A; Mancino M; Gallo M; D'Alessio A; Menard S
Breast Cancer Res Treat; 2008 Nov; 112(1):25-33. PubMed ID: 18060492
[TBL] [Abstract][Full Text] [Related]
23. Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases.
Kai K; Kondo K; Wang X; Xie X; Pitner MK; Reyes ME; Torres-Adorno AM; Masuda H; Hortobagyi GN; Bartholomeusz C; Saya H; Tripathy D; Sen S; Ueno NT
Mol Cancer Ther; 2015 Dec; 14(12):2687-99. PubMed ID: 26443806
[TBL] [Abstract][Full Text] [Related]
24. The scaffolding protein NHERF1 sensitizes EGFR-dependent tumor growth, motility and invadopodia function to gefitinib treatment in breast cancer cells.
Bellizzi A; Greco MR; Rubino R; Paradiso A; Forciniti S; Zeeberg K; Cardone RA; Reshkin SJ
Int J Oncol; 2015 Mar; 46(3):1214-24. PubMed ID: 25530180
[TBL] [Abstract][Full Text] [Related]
25. Metalloprotease-dependent activation of EGFR modulates CD44
Wise R; Zolkiewska A
Breast Cancer Res Treat; 2017 Nov; 166(2):421-433. PubMed ID: 28791489
[TBL] [Abstract][Full Text] [Related]
26. ANXA2 could act as a moderator of EGFR-directed therapy resistance in triple negative breast cancer.
Zhang Y; Bi J; Zhu H; Shi M; Zeng X
Biosci Biotechnol Biochem; 2018 Oct; 82(10):1733-1741. PubMed ID: 29912633
[TBL] [Abstract][Full Text] [Related]
27. The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells.
Nakai K; Xia W; Liao HW; Saito M; Hung MC; Yamaguchi H
Breast Cancer; 2018 Jan; 25(1):74-80. PubMed ID: 28643125
[TBL] [Abstract][Full Text] [Related]
28. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
29. Integrin β1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer.
Choi C; Kwon J; Lim S; Helfman DM
Oncotarget; 2016 Sep; 7(39):63466-63487. PubMed ID: 27563827
[TBL] [Abstract][Full Text] [Related]
30. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
32. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.
Bartholomeusz C; Oishi T; Saso H; Akar U; Liu P; Kondo K; Kazansky A; Krishnamurthy S; Lee J; Esteva FJ; Kigawa J; Ueno NT
Mol Cancer Ther; 2012 Feb; 11(2):360-9. PubMed ID: 22144664
[TBL] [Abstract][Full Text] [Related]
33. IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.
Merrouche Y; Fabre J; Cure H; Garbar C; Fuselier C; Bastid J; Antonicelli F; Al-Daccak R; Bensussan A; Giustiniani J
Oncotarget; 2016 Aug; 7(33):53350-53361. PubMed ID: 27462789
[TBL] [Abstract][Full Text] [Related]
34. Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines.
Ma BB; Lui VW; Cheung CS; Lau CP; Ho K; Hui EP; Tsui SK; Ng MH; Cheng SH; Ng PK; Tsao SW; Chan AT
Invest New Drugs; 2013 Feb; 31(1):30-8. PubMed ID: 22565394
[TBL] [Abstract][Full Text] [Related]
35. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
[TBL] [Abstract][Full Text] [Related]
36. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
[TBL] [Abstract][Full Text] [Related]
37. Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells.
El Guerrab A; Bamdad M; Bignon YJ; Penault-Llorca F; Aubel C
Mol Carcinog; 2017 May; 56(5):1383-1394. PubMed ID: 27864890
[TBL] [Abstract][Full Text] [Related]
38. Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer.
Madden JM; Mueller KL; Bollig-Fischer A; Stemmer P; Mattingly RR; Boerner JL
Breast Cancer Res Treat; 2014 Sep; 147(2):283-93. PubMed ID: 25129346
[TBL] [Abstract][Full Text] [Related]
39. Estrogen receptor-α36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells.
Wang X; Zheng N; Dong J; Wang X; Liu L; Huang J
J Steroid Biochem Mol Biol; 2017 Jul; 171():318-327. PubMed ID: 28529129
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
